Dentist Busted: DEA Yanks License for Sketchy Drug Forms
Published Date: 2/14/2025
Notice
Summary
Dr. Robert L. Carter, a dentist from Delaware, lost his DEA license because he lied on his renewal forms and didn’t meet public safety standards. His new application to work in New Jersey was also denied, mainly because he lacks the proper state permission and has a history of falsifying documents. This means he can’t legally handle controlled substances in either state, affecting his dental practice and career starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Dentist's DEA Registration Revoked
The DEA revoked Robert L. Carter's Certificate of Registration No. BC5574048 and denied his application No. W20128194C and any other pending application for registration in Delaware or New Jersey. The Order is effective March 17, 2025, and means Dr. Carter cannot legally hold a DEA registration to handle, prescribe, or dispense controlled substances in Delaware or New Jersey.
Falsified Applications and Unlawful Prescribing
The DEA found Dr. Carter materially falsified multiple DEA renewal applications (including false answers on renewals dated 2009, 2012, 2015, 2018, and 2021) and issued eight controlled-substance prescriptions on New Jersey prescription pads between June 19, 2019 and November 28, 2020 while his DEA registration was registered to Delaware. Those findings under 21 U.S.C. 824(a)(1) and 824(a)(4)/823(g) supported revocation and denial.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-02621, Commercial Customs Operations Advisory Committee
The Commercial Customs Operations Advisory Committee (COAC) is holding a public meeting on March 5, 2025, in Atlanta and online. This meeting lets businesses and the public share ideas about customs operations, helping improve trade and border processes. If you want to join or comment, sign up by February 28, 2025—no fees involved, just your voice!
Next: 2025-02624, Certain Corrosion-Resistant Steel Products From the Republic of Korea: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Review; Notice of Amended Final Results
The U.S. Court of International Trade changed the subsidy rates for certain Korean steel companies after reviewing the 2019 countervailing duty case. This means KG Dongbu Steel and its related companies will see updated duty rates starting January 27, 2025. If you’re involved with these steel products, watch for changes that could affect costs and trade rules.